Syncromune's AACR late-breaker of phase 1 data for the SYNC-T immunotherapy drug-device combo in mCRPC

blonca9
Apr 8, 2024
1 min read

CEO Eamonn Hobbs describes early responses being seen in the trial and explains how this needle-like device and combination of immunotherapy drugs works.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Syncromune's AACR late-breaker of phase 1 data for the SYNC-T immunotherapy drug-device combo in mCRPC

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight